| __timestamp | Eli Lilly and Company | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4932500000 | 22732000 |
| Thursday, January 1, 2015 | 5037200000 | 29245000 |
| Friday, January 1, 2016 | 5654900000 | 33206000 |
| Sunday, January 1, 2017 | 6070200000 | 31152000 |
| Monday, January 1, 2018 | 4681700000 | 10136000 |
| Tuesday, January 1, 2019 | 4721200000 | 45546000 |
| Wednesday, January 1, 2020 | 5483300000 | 43367000 |
| Friday, January 1, 2021 | 7312800000 | 81413000 |
| Saturday, January 1, 2022 | 6629800000 | 139304000 |
| Sunday, January 1, 2023 | 7082200000 | 192361000 |
| Monday, January 1, 2024 | 8418299999 | 159417000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical industry, understanding cost structures is crucial. Eli Lilly and Company, a stalwart in the sector, has consistently demonstrated robust financial management. From 2014 to 2023, Eli Lilly's cost of revenue has seen a steady increase, peaking in 2021 with a 48% rise from 2014. This growth reflects their strategic investments in research and development, as well as production efficiencies.
Conversely, Halozyme Therapeutics, Inc., a smaller player, has shown a remarkable 747% increase in cost of revenue over the same period. This surge, particularly notable in 2023, underscores their aggressive expansion and scaling efforts. While Eli Lilly's costs are significantly higher, Halozyme's rapid growth trajectory highlights its potential in the biotech arena.
These trends offer a fascinating glimpse into how different strategies impact financial outcomes in the pharmaceutical industry.
Analyzing Cost of Revenue: Eli Lilly and Company and GSK plc
Cost Insights: Breaking Down Eli Lilly and Company and Pfizer Inc.'s Expenses
Cost of Revenue Comparison: Eli Lilly and Company vs Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Eli Lilly and Company and BeiGene, Ltd.
Eli Lilly and Company vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Comparing SG&A Expenses: Eli Lilly and Company vs Halozyme Therapeutics, Inc. Trends and Insights
Cost Insights: Breaking Down Eli Lilly and Company and Bausch Health Companies Inc.'s Expenses
Cost Insights: Breaking Down Novartis AG and Halozyme Therapeutics, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Evotec SE's Expenses